|
[1] DIEHL AM,DAY C. Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med,2017,377(21):2063-2073.
|
|
[2] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.
|
|
[3] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.
|
|
[4] HOUGHTON D,ZALEWSKI P,HALLSWORTH K,et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function[J]. J Hepatol,2019,70(6):1203-1213.
|
|
[5] KARLAS T,PETROFF D,SASSO M,et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis[J]. J Hepatol,2017,66(5):1022-1030.
|
|
[6] European Association for the Study of the Liver(EASI),European Association for the Study of Diabetes(EASD),European Association for the Study of Obesity(EASO). EASL-EASDEASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.
|
|
[7] COTLER SJ,GUZMAN G,LAYDEN-ALMER J,et al. Measurement of liver fat content using selective saturation at 3. 0 T[J]. J Magn Reson Imaging,2007,25(4):743-748.
|
|
[8] MENG XY,LI ZY,LI H. Magnetic resonance imaging in evaluating fat content quantitatively:A review[J]. J Chin Clin Med Imaging,2018,29(5):362-365.(in Chinese)孟祥玉，李子英，李慧．磁共振成像技术量化评估脂肪含量的研究进展[J]．中国临床医学影像杂志，2018,29(5):362-365.
|
|
[9] CHENG WH,SOUDABEH FD,JONATHAN CH,et al. Fat Quantification in the Abdomen[J]. Top Magn Reson Imaging,2017,26(6):221-227.
|
|
[10] JOY TR,MCKENZIE CA,TIRONA RG,et al. Sitagliptin in patients with non-alcoholic steatohepatitis:A randomized,placebo-controlled trial[J]. World J Gastroenterol,2017,23(1):141-150.
|
|
[11] LEVIN YS,YOKOO T,WOLFSON T,et al. Effect of echosampling strategy on the accuracy of out-of-phase and inphase multiecho gradient-echo MRI hepatic fat fraction estimation[J]. J Magn Reson Imaging,2014,39(3):567-575.
|
|
[12] PARK CC,NGUYEN P,HERNANDEZ C,et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology,2017,152(3):598-607.
|
|
[13] YOKOO T,SERAI SD,PIRASTEH A,et al. Linearity,bias,and precision of hepatic proton density fat fraction measurements by using MR imaging:A meta-analysis[J]. Radiology,2018,286(2):486-498.
|
|
[14] NOUREDDIN M,LAM J,PETERSON MR,et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials[J].Hepatology,2013,58(6):1930-1940.
|
|
[15] CAUSSY C,REEDER SB,SIRLIN CB,et al. Noninvasive,quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology,2018,68(2):763-772.
|
|
[16] PATEL J,BETTENCOURT R,CUI J,et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis[J]. Therap Adv Gastroenterol,2016,9(5):692-701.
|
|
[17] AJMERA V,PARK CC,CAUSSY C,et al. Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2018,155(2):307-310.
|
|
[18] KANG BK,KIM M,SONG SY,et al. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders:Validation with MRS and histology[J]. Br J Radiol,2018,91(1089):20170378.
|
|
[19] HUI SCN,SO HK,CHAN DFY,et al. Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease[J]. Eur J Radiol,2018,107:7-13.
|
|
[20] FAZELI DEHKORDY S,FOWLER KJ,MAMIDIPALLI A,et al.Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes[J].Eur Radiol,2019,29(5):2474-2480.
|
|
[21] LV S,JIANG S,LIU S,et al. Noninvasive quantitative detection methods of liver fat content in nonalcoholic fatty liver disease[J]. J Clin Transl Hepatol,2018,6(2):217-221.
|
|
[22] JANG JK,LEE SS,KIM B,et al. Agreement and reproducibility of proton density fat fraction measurements using commercial MR sequences across different platforms:A multivendor,multi-institutional phantom experiment[J]. Invest Radiol,2019,54(8):517-523.
|
|
[23] STERN C,CASTERA L. Non-invasive diagnosis of hepatic steatosis[J]. Hepatol Int,2017,11(1):70-78.
|
|
[24] HUIJBERS A,WANTEN G,DEKKER HM,et al. Noninvasive quantitative assessment of hepatic steatosis by proton magnetic resonance spectroscopy among adult patients receiving home parenteral nutrition[J]. JPEN J Parenter Enteral Nutr,2018,42(4):778-785.
|
|
[25] DULAI PS,SIRLIN CB,LOOMBA R. MRI and MRE for noninvasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH:Clinical trials to clinical practice[J].J Hepatol,2016,65(5):1006-1016.
|
|
[26] LEE DH. Imaging evaluation of non-alcoholic fatty liver disease:Focused on quantification[J]. Clin Mol Hepatol,2017,23(4):290-301.
|
|
[27] RUNGE JH,SMITS LP,VERHEIJ J,et al. MR spectroscopyderived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis[J]. Radiology,2018,286(2):547-556.
|
|
[28] CAO Q,XU S,LI S,et al. Quantification of hepatic lipid using7. 0T proton magnetic resonance spectroscopy and computed tomography in mild alcoholic steatotic mice[J]. J Liver,2018,7(4):234.
|
|
[29] SHENOY-BHANGLE A,BALIYAN V,KORDBACHEH H,et al. Diffusion weighted magnetic resonance imaging of liver:Principles,clinical applications and recent updates[J]. World J Hepatol,2017,9(26):1081-1091.
|
|
[30] GUIU B,PETIT JM,CAPITAN V,et al. Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver:A 3. 0-T MR study[J]. Radiology,2012,265(1):96-103.
|
|
[31] LEE Y,KIM H. Assessment of diffusion tensor MR imaging(DTI)in liver fibrosis with minimal confounding effect of hepatic steatosis[J]. Magn Reson Med,2015,73(4):1602-1608.
|
|
[32] LI C,YE J,PENG Y,et al. Evaluation of diffusion kurtosis imaging in stratification of nonalcoholic fatty liver disease and early diagnosis of nonalcoholic steatohepatitis in a rabbit model[J].Magn Reson Imaging,2019,63:267-273.
|
|
[33] JOO I,LEE JM,YOON JH,et al. Nonalcoholic fatty liver disease:Intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model[J]. Radiology,2013:122506.
|
|
[34] MURPHY P,HOOKER J,ANG B,et al. Associations between histologic features of nonalcoholic fatty liver disease(NAFLD)and quantitative diffusion-weighted MRI measurements in adults[J]. J Magn Reson Imaging,2015,41(6):1629-1638.
|
|
[35] SHIN HJ,YOON H,KIM MJ,et al. Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children[J]. World J Gastroenterol,2018,24(27):3013-3020.
|
DownLoad: